Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2021-08-24
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice.

1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2） Long-term safety (particularly, malignant tumors and serious infections) and efficacy

Occurrences of malignant tumors and serious infections will be compared with a control group.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Antirheumatic Agents; Etanercept; Tofacitinib

Criteria

Inclusion Criteria:

• All patients receiving Tofacitinib (Xeljanz)

Exclusion Criteria:

Not Applicable